2019年10月12日(土) 08:40 〜 10:20 第11会場 (502)

Organizer / Chair: ‌Tetsuro OHMORI (Department of Psychiatry, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan), Co-chair: Yasunori MORIO (Translational Medical Center, National Center of Neurology and Psychiatry, Japan), Discussants: ‌Kotaro HATTORI (Medical Genome Center, National Center of Neurology and Psychiatry, Japan), Tetsurou KIKUCHI (New Drug Research Division, Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd., Japan)

Schizophrenia is a complex psychiatric disorder with a lifetime morbidity rate of 0.5 ―1.0%. Despite the etiological complexities of schizophrenia, accumulating evidence suggests that glutamatergic disturbances, inflammation, and alterations in one-carbon metabolism might play key roles in the pathophysiologies of schizophrenia, which in turn helps us identify novel therapeutic targets. In this session, we will present our latest preclinical and human research findings to discuss novel therapeutic strategies for treatment of schizophrenia and associated psychiatric conditions.